摘要
目的:研究血管活性物质改变在肝硬化门静脉高压发生发展中的意义。方法:住院肝硬化门静脉高压患者36例,以健康者24例为对照。采用放射免疫法检测血浆ADM、ET-1浓度,硝酸还原酶法检测血清NO浓度。彩色多普勒检测门静脉系统血流动力学指标。结果:肝硬化患者ADM、NO浓度明显升高;ET-1浓度明显降低。肝硬化组门静脉内径显著增宽,血流量明显升高;峰值血流速度明显降低。ADM及NO浓度与门静脉血流量里正相关;ET-1浓度与门静脉血流量呈负相关。结论:肝硬化时存在明显的血管物质代谢紊乱,扩血管物质明显增加,与门静脉血流量增加关系密切。血管活性物质浓度的改变在肝硬化门静脉高压的发生中起着重要作用。
Objective：To study the changes of AdrenomeduUin（ADM）.NO and ET-1 in portal hypertension and its role.Methods：36 cirrhosis patients and 24 normal subjects were investigated. Plasma concentrations of ADM and ET-1 were measured by radi say.Serum NO concentration was measured by the method of nitric acid reductase.The portal vein hemodynamic changes were observed by color Doppler ultrasound.Results：Plasma concentrations of ADM and NO were significantly higher in the cirrhosis patients （tADM=1.93, P〈0.05 and tNO=1.76,P〈0.05）.The concentration of ET-1 was significantly decreased （t=1.69,P〈0.05）.The portal vein diameter and blood flow volume were significantly higher in the cirrhosis patients （tD=1.68,P〈0.05 and tQ=2.02,P〈0.05）. The Vmax was significantly decreased （t=1.85,P〈0.05）. ADM and NO levels were positively correlated with blood flow volume （r=0.43,P〈0.05）.ET-1 was negatively correlated with blood flow volume （r=-0.72,P〈0.05）.Condusion：There were significantly vaso-active substances metabolism disorder in cirrhosis patients. Vasodilator substances were increased and positively correlated with the increase of portal vein blood flow volume.The changes of vaso-active substances levels may play an important role in portal hypertension.
出处
《现代医药卫生》
2007年第1期6-8,共3页
Journal of Modern Medicine & Health
关键词
肝硬化
门静脉
血管活性物质
Cirrhosis
Portal vein
AdrenomeduUin
NO
ET-1
